Evidence map›Paper›PMID 31941773›Full record

ArticleJournal of virology2020

A Conserved Acidic-Cluster Motif in SERINC5 Confers Partial Resistance to Antagonism by HIV-1 Nef.

Charlotte A Stoneham, Peter W Ramirez, Rajendra Singh, Marissa Suarez, Andrew Debray, Christopher Lim, Xiaofei Jia, Yong Xiong, John Guatelli

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. SERINC5 counters retroviruses and non-retroviruses.Frontiers in cellular and infection microbiology · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Charlotte A Stoneham *Department of Medicine, University of California San Diego, La Jolla, California, USA.
Peter W Ramirez *Department of Medicine, University of California San Diego, La Jolla, California, USA.
Rajendra SinghDepartment of Medicine, University of California San Diego, La Jolla, California, USA.
Marissa SuarezThe VA San Diego Healthcare System, San Diego, California, USA.
Andrew DebrayDepartment of Medicine, University of California San Diego, La Jolla, California, USA.
Christopher LimDepartment of Molecular Biophysics and Biochemistry, Yale University, New Haven, Connecticut, USA.
Xiaofei JiaDepartment of Chemistry and Biochemistry, University of Massachusetts Dartmouth, Dartmouth, Massachusetts, USA.
Yong XiongDepartment of Molecular Biophysics and Biochemistry, Yale University, New Haven, Connecticut, USA.
John GuatelliDepartment of Medicine, University of California San Diego, La Jolla, California, USA jguatelli@ucsd.edu.
University of California, San Diego · USVA San Diego Healthcare System · USYale University · USUniversity of Massachusetts Dartmouth · US

Funding

UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SONIA JAIN · 1994 to 2026
$78.4M
UCSD/SDSU IRACDAK12GM068524 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TREJO, JOANN · 2003 to 2025
$24.4M
Enhancement of Infectivity by HIV-1 Nef via Antagonism of SERINC ProteinsR01AI129706 · NIAID · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI GUATELLI, JOHN C. · 2017 to 2021
$2.8M
NCATS NIH HHS UL1 TR001442NIAID NIH HHS P30 AI036214NIAID NIH HHS R01 AI129706NIGMS NIH HHS K12 GM068524
6 · The paper itself

Abstract

The cellular protein SERINC5 inhibits the infectivity of diverse retroviruses, and its activity is counteracted by the glycosylated Gag (glycoGag) protein of murine leukemia virus (MLV), the S2 protein of equine infectious anemia virus (EIAV), and the Nef protein of human immunodeficiency virus type 1 (HIV-1). Determining the regions within SERINC5 that provide restrictive activity or Nef sensitivity should inform mechanistic models of the SERINC5/HIV-1 relationship. Here, we report that deletion of the conserved sequence EDTEE, which is located within a cytoplasmic loop of SERINC5 and which is reminiscent of an acidic-cluster membrane trafficking signal, increases the sensitivity of SERINC5 to antagonism by Nef, while it has no effect on the intrinsic activity of the protein as an inhibitor of infectivity. These effects correlated with enhanced removal of the ΔEDTEE mutant relative to that of wild-type SERINC5 from the cell surface and with enhanced exclusion of the mutant protein from virions by Nef. Mutational analysis indicated that the acidic residues, but not the threonine, within the EDTEE motif are important for the relative resistance to Nef. Deletion of the EDTEE sequence did not increase the sensitivity of SERINC5 to antagonism by the glycoGag protein of MLV, suggesting that its virologic role is Nef specific. These results are consistent with the reported mapping of the cytoplasmic loop that contains the EDTEE sequence as a general determinant of Nef responsiveness, but they further indicate that sequences inhibitory to as well as supportive of Nef activity reside in this region. We speculate that the EDTEE motif might have evolved to mediate resistance against retroviruses that use Nef-like proteins to antagonize SERINC5.

Indexed as

AllelesAmino Acid MotifsCytoplasmGene DeletionGlycosylationHEK293 CellsHeLa CellsHIV-1HumansInfectious Anemia Virus, EquineJurkat CellsMembrane ProteinsMoloney murine leukemia virusMutationnef Gene Products, Human Immunodeficiency VirusProtein DomainsMembrane Proteinsnef Gene Products, Human Immunodeficiency Virusnef protein, Human immunodeficiency virus 1SERINC5 protein, humanHIV-1NefSERINC

Identifiers

PMID31941773
PMCPMC7081897
OpenAlexW2999042057

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.